New hope for rare bleeding disorder: two drug combos face off
NCT ID NCT03384277
Summary
This study compared two treatment combinations to eliminate harmful antibodies in people with acquired hemophilia A, a rare bleeding disorder. Sixty-six Chinese patients received either steroids with rituximab or steroids with cyclophosphamide. Researchers measured which combination was better at removing the antibodies and how long it took to achieve remission.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACQUIRED HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ethics Committee of Blood disease hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300020, China
Conditions
Explore the condition pages connected to this study.